Evidence mapPaperPMID 38104562Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2024

First in vivo base-editing trial shows promise.

Renzhi Han

Abstract readEditorial
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Targeted inhibition ofMolecular therapy. Methods & clinical development · 2025
    Article
  4. Review
  5. Review
  6. Recent advances in therapeutic gene-editing technologies.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  7. Current trends in gene therapy to treat inherited disorders of the brain.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  8. Base editing in humanized dystrophic mice.Molecular therapy. Nucleic acids · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Renzhi HanDepartment of Pediatrics, Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, 980 W Walnut St Joseph E. Walther Hall (R3) C118, Indianapolis, IN 46202, USA. Electronic address: rh11@iu.edu.

Funding

Targeted editing of ASGR1 for cardiovascular diseasesR01HL169976 · INDIANA UNIVERSITY INDIANAPOLIS · 2025 to 2025
$708k
Controllable base editing therapy for DMDR01HL170260 · INDIANA UNIVERSITY INDIANAPOLIS · 2025 to 2025
$600k
NHLBI NIH HHS R01 HL116546NHLBI NIH HHS R01 HL169976NHLBI NIH HHS R01 HL170260NHLBI NIH HHS R21 HL163720
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CRISPR-Cas SystemsGene Editing

Identifiers

PMID38104562
PMCPMC10787164

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.